Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Pdl Biopharma Inc (PDLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 363,172
  • Shares Outstanding, K 120,655
  • Annual Sales, $ 198,110 K
  • Annual Income, $ -68,860 K
  • 60-Month Beta 0.53
  • Price/Sales 1.85
  • Price/Cash Flow 5.55
  • Price/Book 0.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate 0.04
  • Number of Estimates 1
  • High Estimate 0.04
  • Low Estimate 0.04
  • Prior Year 0.10
  • Growth Rate Est. (year over year) -60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.99 +0.67%
on 05/17/19
3.62 -16.74%
on 04/22/19
-0.45 (-13.01%)
since 04/17/19
3-Month
2.99 +0.67%
on 05/17/19
3.89 -22.62%
on 04/11/19
-0.32 (-9.61%)
since 02/15/19
52-Week
2.25 +33.78%
on 09/17/18
3.89 -22.62%
on 04/11/19
+0.28 (+10.26%)
since 05/17/18

Most Recent Stories

More News
PDL BioPharma to Participate at UBS Global Healthcare Conference

PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet, PDL's president and chief executive officer, and Peter Garcia, PDL's chief financial officer, will present at...

PDLI : 3.01 (-0.66%)
PDL BioPharma (PDLI) Q1 Earnings Top Mark, Revenues Rise Y/Y

PDL BioPharma's (PDLI) earnings exceed estimates in the first quarter of 2019. Higher royalty rights as well as product sales lead to a marginal spurt in year-over-year revenues

PDLI : 3.01 (-0.66%)
EVFM : 5.60 (+11.55%)
GILD : 66.36 (+0.88%)
BIIB : 229.28 (-0.69%)
PDL BioPharma Reports 2019 First Quarter Financial Results

PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three months ended March 31, 2019:

PDLI : 3.01 (-0.66%)
Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More

Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.

GH : 76.18 (-0.55%)
PDLI : 3.01 (-0.66%)
MRK : 78.72 (-0.52%)
XLRN : 41.76 (-0.38%)
IONS : 67.40 (-0.56%)
BPMC : 81.30 (+0.26%)
PFE : 41.47 (-0.41%)
Evofem Biosciences Reports First Quarter 2019 Financial Results and Provides Corporate Update

Evofem Biosciences, Inc., (NASDAQ: EVFM) ("Evofem" or the "Company"), a clinical stage biopharmaceutical company, today reported financial results for the three- month period ended March 31, 2019. First...

PDLI : 3.01 (-0.66%)
EVFM : 5.60 (+11.55%)
Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1

Conatus, (CNAT) earnings and revenues lag estimates in the first-quarter of 2019. Emricasan remains in focus.

CNAT : 0.86 (-3.21%)
PDLI : 3.01 (-0.66%)
NVS : 82.70 (+0.30%)
PFE : 41.47 (-0.41%)
Emergent (EBS) Earnings & Revenues Miss Estimates in Q1

Emergent (EBS) incurs loss in the first quarter and misses on revenues as well.

PDLI : 3.01 (-0.66%)
EBS : 44.24 (-2.21%)
GSK : 39.46 (+0.31%)
SNY : 41.90 (+0.58%)
Agios (AGIO) Earnings and Revenues Surpass Estimates in Q1

Agios (AGIO) benefits from earnings as well as revenue beat in first-quarter 2019. However, Tibsovo sales fall sequentially, pulling the stock down.

AGIO : 50.10 (+0.72%)
CELG : 95.42 (-0.09%)
PDLI : 3.01 (-0.66%)
MRUS : 14.41 (-2.57%)
Acorda (ACOR) Earnings and Revenues Beat Estimates in Q1

Acorda's (ACOR) shares rise on earnings and revenue beat in Q1. Inbrija registers first sales figure following its launch in the reported quarter.

MYL : 19.64 (-2.82%)
PDLI : 3.01 (-0.66%)
MRUS : 14.41 (-2.57%)
ACOR : 11.02 (-4.42%)
PDL BioPharma (PDLI) to Post Q1 Earnings: What's in Store?

During PDL BioPharma's (PDLI) Q1 conference call, investor focus will be on the company's ability to acquire new income-generating assets for frequent revenue growth.

PDLI : 3.01 (-0.66%)
HZNP : 25.83 (-4.19%)
NVS : 82.70 (+0.30%)
ADRO : 3.13 (-1.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade PDLI with:

Business Summary

Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital...

See More

Key Turning Points

2nd Resistance Point 3.10
1st Resistance Point 3.06
Last Price 3.01
1st Support Level 2.98
2nd Support Level 2.94

See More

52-Week High 3.89
Fibonacci 61.8% 3.26
Fibonacci 50% 3.07
Last Price 3.01
Fibonacci 38.2% 2.88
52-Week Low 2.25

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar